As the end of the first quarter approaches the question becomes has this recent sell off in MedTech Digital Health run its course or is there more to come. To us it’s a split answer as we see more selling in Digital Health and a buying opportunity in the diabetes device area. Let’s take a closer look at the reasons why and let’s start with digital health.
Covid isn’t over yet but signs are beginning to emerge that after a long hiatus people are going back to the doctor’s office. Yes it’s still early . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.